Chronic hepatitis B virus (HBV) is a debilitating infectious disease of the liver that afflicts over 250 million people worldwide and is a leading cause of chronic liver disease and liver transplants. It is a global epidemic that impacts more people than hepatitis C virus (HCV) and HIV infection combined, with a higher mortality and morbidity rate.
An estimated 500,000 to one million people die every year from HBV-related causes. The Centers for Disease Control (CDC) reports that approximately one and a half million people in the US are chronically infected with HBV. There is a high unmet need for curative therapies for chronic HBV—the current standard of care is unable to cure the condition in more than 90% of patients.
Assembly is advancing multiple Core Protein Allosteric Modifiers (CpAMs) derived from distinct chemical series with a focus on increasing functional cure rates for patients with chronic hepatitis B virus infection. CpAMs have an effect on multiple points in the HBV lifecycle where core protein plays a role, including the establishment of cccDNA.
Building on the early work of scientific founder Adam Zlotnick, Assembly's lead molecule, ABI-H0731, has shown potent activity across multiple viral genotypes and is currently in a Phase 1b trial. ABI-H2158 is the company's second CpAM candidate, and Assembly will continue to optimize and select additional CpAMs to undergo further studies. More information about our clinical trials can be found at www.clinicaltrials.gov.